Elizabeth Wulff-Burchfield: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

• The congress is free to attend.
• Register via the link.

Co-Chair of VIRO

Images

Name

Rana McKay Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on  “Future Directions: Emerging Agents and Combinations.” She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Elizabeth Wulff-Burchfield

Dr. Wulff-Burchfield is an Associate Professor and Medical Oncologist at the University of Kansas Health System.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Wulff-Burchfield will present on “Palliative Care Integration in Advanced RCC.” Her presentation will highlight:

• The role of palliative care in comprehensive management of advanced renal cell carcinoma.
• Strategies for symptom management and improving patient well-being throughout treatment.
• Approaches to personalized care that align with patient goals and quality of life priorities.
• Collaborative multidisciplinary models that enhance support for patients and families.

Dr. Wulff-Burchfield combines clinical expertise in oncology and palliative medicine with research aimed at improving symptom control and supportive care, advocating for compassionate, patient-centered treatment in advanced RCC.

Global Voices in Renal Oncology (VIRO) 2025